Mindpeak, a Global leader in Artificial Intelligence in pathology, today announced that its new product "AI Console" has received the CE-Mark. The "AI Console" viewer enables optimal on-screen display of analysis results from Mindpeak's AI-assisted cancer diagnostic tools, such as the CE-marked BreastIHC. "With our new AI Console, we offer experts - especially pathologists - an optimised display of our AI results. For example, the data and information that is crucial for the pathologist - such as the distinction between tumorous cells and non-tumorous cells - is highlighted in the user interface," explains Mindpeaks CEO Felix Faber. The user interface works quickly, is very responsive and enables a particularly well processable and interpretable display of the image data. In addition, the AI Console is designed to integrate particularly well with other image management systems.
This Year, Mindpeak received its CEMark for BreastIHC, making it the first company with a CE certified Deep Learning solution that can distinguish tumorous and non-tumorous structures on a cellular level. The CE-Mark for in-vitro-diagnostic medical devices confirms that BreastIHC complies with all essential health and safety requirements of all applicable EU directives. It makes the software available to pathology practices across Europe and helps meet the challenge of increasing demand for cancer diagnostics as the number of pathologists declines.
BreastIHC is a plug-and-play solution that enables pathology laboratories to immediately detect, classify and quantify breast cancer cells without the need for complex set-up and calibration procedures. BreastIHC classifies cells into positively stained tumor and unstained tumor cells. One of its great advantages is its ability to differentiate between tumorous and non-tumorous structures, improving the scoring in the tumor microenvironment. "Our algorithm has proven in various tests that it works reliably under a wide range of laboratory conditions and can increase reporting speed and throughput enormously", says Faber.
This Year, Mindpeak received its CEMark for BreastIHC, making it the first company with a CE certified Deep Learning solution that can distinguish tumorous and non-tumorous structures on a cellular level. The CE-Mark for in-vitro-diagnostic medical devices confirms that BreastIHC complies with all essential health and safety requirements of all applicable EU directives. It makes the software available to pathology practices across Europe and helps meet the challenge of increasing demand for cancer diagnostics as the number of pathologists declines.
BreastIHC is a plug-and-play solution that enables pathology laboratories to immediately detect, classify and quantify breast cancer cells without the need for complex set-up and calibration procedures. BreastIHC classifies cells into positively stained tumor and unstained tumor cells. One of its great advantages is its ability to differentiate between tumorous and non-tumorous structures, improving the scoring in the tumor microenvironment. "Our algorithm has proven in various tests that it works reliably under a wide range of laboratory conditions and can increase reporting speed and throughput enormously", says Faber.
